Skip to main content

ORIGINAL RESEARCH article

Front. Pediatr.
Sec. Pediatric Oncology
Volume 13 - 2025 | doi: 10.3389/fped.2025.1502761
This article is part of the Research Topic Emerging Strategies in Pediatric Hepatoblastoma Care: A Multidisciplinary Approach View all articles

Outcomes of liver transplantation of hepatoblastoma: single-center data in mainland China

Provisionally accepted
Hongting Huang Hongting Huang Linman Li Linman Li Jianjun Zhu Jianjun Zhu Dongwei Xu Dongwei Xu Ping Wan Ping Wan Bijun Qiu Bijun Qiu Jiaxu Zhang Jiaxu Zhang Yongkang Yang Yongkang Yang Jie Zhao Jie Zhao Jianjun Zhang Jianjun Zhang Yi Luo Yi Luo Mingxuan Feng Mingxuan Feng Qiang Xia Qiang Xia *
  • Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

The final, formatted version of the article will be published soon.

    HB is the most common liver malignancy in children. Giving the rarity of the research reporting outcomes of LT for HB in China, updated long-term data are needed. The primary objective was to evaluate the outcomes of liver transplantation in HB. The secondary objective was to assess the clinical parameters that influence the outcomes of liver transplantation in HB.We retrospectively analyzed the dataset of a single-center cohort from RJ-SJTUM. Outcomes were OS and PFS. Cox proportional hazard models were used to estimate mortality adjusted HRs with 95% CIs.RJ-SJTUM has accounted for 68.5% of the total cases in China since 2019. The 5-year PFS and OS rates were 63.6% and 84.6% respectively. AFP≥13686.5ng/ml before LT was an independent risk factor for PFS (P<0.001), and distal metastasis before LT was an independent risk factor for OS (P=0.028). All patients received post-LT chemotherapy, and two patients experienced severe liver injury. Patients with localized tumor recurrence after LT had favorable outcomes if radical resection of the recurrence was achieved. Sirolimus played a role in prolonging the survival of patients with recurrent HB after LT (P=0.0307).LT achieved favorable outcomes for patients with locally advanced hepatoblastoma. This study suggests that a judicious patient selection to exclude patients with high-risk predictors, as well as standardized postoperative management is critical in this process.

    Keywords: Hepatoblastoma, Liver Transplantation, liver resection, Immune suppresion, Tumor metastases

    Received: 27 Sep 2024; Accepted: 15 Jan 2025.

    Copyright: © 2025 Huang, Li, Zhu, Xu, Wan, Qiu, Zhang, Yang, Zhao, Zhang, Luo, Feng and Xia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Qiang Xia, Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200000, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.